Phase 2 Study of Valproic Acid and Simvastatin With Gemcitabine and Nab-paclitaxel Regimens in Untreated Metastatic Pancreatic Cancer Patients
Led by National Cancer Institute, Naples · Updated on 2026-04-14
240
Participants Needed
5
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether combining valproic acid VPA and simvastatin SIM with standard chemotherapy regimens can improve treatment outcomes for patients with untreated metastatic pancreatic ductal adenocarcinoma mPDAC. This phase 2, randomized, open-label study aims to determine if this combination extends progression-free survival compared to chemotherapy alone. The study also includes correlative analyses on tumor and blood samples to find biomarkers that might predict treatment response or side effects, potentially guiding personalized therapy.
Participants receive one of two chemotherapy regimens nab-paclitaxel with gemcitabine AG or nab-paclitaxel with gemcitabine, cisplatin, and capecitabine PAXG. Alongside chemotherapy, the experimental group takes a daily fixed dose of 20 mg simvastatin plus valproic acid with dose adjustments to reach target blood levels. Treatments start within three days of randomization and are given in 28-day cycles for up to six cycles or until disease progression, unacceptable toxicity, or other reasons for stopping. Patients showing clinical benefit may continue treatment beyond six cycles. After treatment, all participants enter a follow-up period.
During the study, researchers monitor patients for progression-free survival over 40 months along with tumor response, survival, toxicity, and quality of life. Assessments include imaging tests to measure disease status and blood tests for safety and biomarker evaluation. Follow-up lasts up to 10 months after enrollment for primary outcome evaluation, with patients followed until death to collect further treatment data. This thorough monitoring aims to understand both effectiveness and safety of the combination treatment in real-world settings.
CONDITIONS
Brief Title
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
Research Team
A
Antonio Avallone
A
Alessandra Leone
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent for study procedures and correlative studies
Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
No prior treatments for pancreatic cancer (chemotherapy, radiation, or surgery)
Age 18 years or older, any sex
ECOG Performance Status of 0 or 1 at study entry
Measurable disease by imaging according to RECIST 1.1 criteria
Known dihydropyrimidine dehydrogenase (DPD) activity for patients in the PAXG regimen
Adequate bone marrow function: ANC ≥ 1.5 x 10^9/L, platelets ≥ 100 x 10^9/L, hemoglobin ≥ 9 g/dL
Adequate liver function: total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 2 with biliary stent; AST/ALT ≤ 5 x ULN
Adequate renal function: serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min in males and ≥ 50 mL/min in females
You will not qualify if you...
Prior malignancy within one year except certain skin cancers or in situ cervical cancer
Prior chemotherapy or other medical treatment for metastatic pancreatic cancer (adjuvant chemotherapy allowed if ended > 6 months ago)
Previous treatment with HDAC inhibitors or valproic acid
Use of statins, fibrates, or cholesterol medications within 3 months before study
Known hypersensitivity to statins or any study medications
Major surgery within 4 weeks before enrollment
Pregnancy or breastfeeding
Brain metastases
Hepatitis or severe liver disorder
Severe or uncontrolled systemic disease or conditions that interfere with study compliance
Long QT syndrome or QTc interval > 480 msec or use of QTc-prolonging drugs
History of poor cooperation, non-compliance, or inability to understand consent
Participation in other interventional drug or device studies within 30 days
Inability to take oral medications or conditions affecting absorption
Sexually active individuals unwilling to use contraception during treatment and for 6 months after last dose
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 6 cycles of 28 days each
Participants receive chemotherapy regimens including gemcitabine and nab-paclitaxel-based treatments, with or without valproic acid and simvastatin, for up to 6 cycles or until disease progression, unacceptable toxicity, physician's decision, or withdrawal.
Visits at the start of each 28-day cycle (up to 6 visits)
Follow-up
Duration - Up to 10 months after treatment
Participants are monitored after treatment ends for up to 10 months to assess progression-free survival and other outcomes until death or study completion.
Periodic visits during follow-up as determined by study team
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Safety and Effectiveness of Total Pancreatectomy With Islet Autotransplantation for Treating Resectable Pancreas Region Adenocarcinoma at High Risk of Postoperative Fistula
Evaluating 3D Imaging Versus CT Scans for Assessing Neoadjuvant Treatment Response in Borderline and Locally Advanced Pancreatic Adenocarcinoma
Phase 12 Study of Pre-Surgery mFOLFIRINOX with Oral Hydroxychloroquine in Treating Resectable Pancreatic Adenocarcinoma
Phase II Trial of Surgery After Chemotherapy with NALIRIFOX for Pancreatic Cancer with Limited Liver or Lung Metastases
Evaluating the Safety of the HistoSonics Edison System Using Histotripsy to Treat Unresectable Pancreatic Adenocarcinoma
Phase 2 Study of Valproic Acid and Simvastatin With Gemcitabine and Nab-paclitaxel Regimens in Untreated Metastatic Pancreatic Cancer Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.